Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Immuneering Corp (NASDAQ:IMRX) Chief Scientific Officer Brett Matthew Hall reported purchasing shares of Class A Common Stock in two transactions, totaling $34,616. The insider buying comes as InvestingPro data shows the stock has surged 34% in the past week, with analysts maintaining a bullish stance and a median price target suggesting significant upside potential. On June 20, 2025, Hall acquired 7,415 shares at a price of $2.6999 each. Followed by another purchase on June 23, 2025, Hall bought 6,007 shares within a price range of $2.4101 to $2.4299, with a weighted average price of $2.4299
In other recent news, Immuneering Corporation announced positive results from its Phase 2a clinical trial of atebimetinib for first-line pancreatic cancer. The trial demonstrated a 94% overall survival rate and a 72% progression-free survival rate at six months, surpassing the standard care benchmarks of 67% and 44%, respectively. The company reported a 39% overall response rate and an 81% disease control rate, with some patients experiencing significant tumor regression. Mizuho (NYSE:MFG) raised its price target for Immuneering to $10 from $8, maintaining an Outperform rating due to the promising trial results. The firm described the drug as having a favorable safety profile and increased its probability of success assumption for the treatment. Immuneering plans to increase target enrollment in the trial and aims to start a pivotal trial in 2026. Additionally, Immuneering held its Annual Meeting of Stockholders, electing three Class I directors and ratifying its independent public accounting firm. The company plans to seek regulatory feedback on its pivotal study plans in late 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.